Drug makers have embraced artificial intelligence and machine learning (AI/ML) for discovering and developing new drugs, but it requires significant investment. A recent report from Accenture aims to quantify the advantages, including cutting down on cycle times and costs, and suggests these efficiencies could shave four years off of development time.
AI/ML Efficiency Gains Could Add Billions To Drug Revenues, Report Finds
A report from Accenture, based on interviews with 75 R&D execs from large biopharma companies, found adopting the technology could cut costs by up to 45%.
